Health & Fitness
Health and Fitness
Health and Fitness
Thu, October 6, 2011
Wed, October 5, 2011
Tue, October 4, 2011
Mon, October 3, 2011
Finkelstein Thompson LLP Announces Investigation of Pharmaceutical Product Development, Inc.
WASHINGTON--([ BUSINESS WIRE ])--The law firm of Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Pharmaceutical Product Development, Inc. (aPPDIa or the aCompanya) (NASDAQ: PPDI), concerning the proposed acquisition of the Company by the Carlyle Group and Hellman & Friedman. Under the terms of the transaction, shareholders would receive $33.25 per share in cash, in a deal worth approximately $3.8 billion.
PPDI has performed well recently, posting earnings numbers up 10% from last year for the quarter ending June 30. Indeed, at least one analyst has set a target price of $38.00 for the Companya™s stock.
The investigation is focused on the potential unfairness of the consideration to PPDIa™s shareholders, the process by which the Companya™s Board of Directors considered the transaction, and potential conflicts of interests among PPDIa™s Board members.
If you are interested in discussing your rights as a PPDI shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at [ contact@finkelsteinthompson.com ].
Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in financial litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers.
To learn more about Finkelstein Thompson LLP, please visit our web site at [ www.finkelsteinthompson.com ]. Attorney advertising. Prior results do not guarantee similar outcomes.
